Irinotecan Hydrochloridis Trihydratorum CAS 136572-09-3 API Factory High Munditia
Manufacturer Supple Irinotecan ac intermedia:
Irinotecan hydrochloridum CAS: 100286-90-6
Irinotecan Free Base CAS: 97682-44-5
Irinotecan Hydrochloridis Trihydratorum CAS: 136572-09-3
7-Ethyl-10-Hydroxycamptothecinum CAS: 86639-52-3
1-Chlorocarbonyl-4-Piperidinopiperidium hydrochloridum CAS: 143254-82-4
| Nomen chemicum | Irinotecan Hydrochloride Trihydrate |
| Synonyma | Irinotecan HCl Trihydrate;ANT-11 Trihydrate;Irinotecan HCL 3H2O |
| CAS Number | 136572-09-3 |
| CATTUS Number | RF-API52 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C33H38N4O6·HCl·3H2O |
| M. Pondus | 677.20 |
| Liquescens punctum | 250.0~ 256.0℃ (decl.); |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Lux aut Yellow Crystallina pulveris |
| Incassum (w/w) | 98.0%~ 102.0% |
| Munditia (HPLC) | ≥99.5% |
| Solubilitas | Leviter solutum in aqua, ethanolum vel chloroforme, in acetono fere insolubile |
| Lepidium sativum | per IR et HPLC, Conforms |
| Imprimis Rotatione Optica | +60°~+73° |
| Aqua | 7.0%~9.0% |
| Residuum solventium | Prosequitur ICH Requirements |
| Residere in Ignition | ≤0.20% |
| Chloride | 5.0%~6.0% |
| PH Precium | 3.0~5.0 |
| Metalla gravis | ≤20ppm |
| Individual Impurities | ≤0.10% |
| Totalis immunditias | ≤0.50% |
| Repono Condition | Condite in 2-8°C, In vasis obsignatis et a lumine et humore custodiendis |
| Test Standard | Enterprise Standard |
| Consuetudinem | Active Pharmaceutical Ingredient (API) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum hydrochloridi trihydratorum Irinotecani (CAS: 136572-09-3) cum qualitate magna.
Irinotecan hydrochloridum trihydratum est topoisomerase I inhibitor maxime adhibitus ut cancer colon et cancer rectalis tractaturus sit, ne religatio de DNA strati ligando ad complexum topoisomerasi I-DNA adhibitum sit.lrinotecan hydrochloridum, semi-syntheticum, aqua solutum derivativum camptothecin agentis potentis anticancri, in Iaponia deductum est ad curationem pulmonis, ovarii, et carcinomata ceruicis.lrinotecan suam actionem antitumorem exercet per inhibitionem topoisomerasi I, enzyme celluloso, quod involvitur ad conservandam structuram topographicam DNA in processu translationis, transcriptionis et mitosis.lrinotecan subit de-esterificationem in vivo cedere metabolite activo, SN 38, qui est M-trina potentior quam parens.Etsi multo minus toxici quam camptothecin, notabilis numerus aegrotorum in iudiciis clinicis exhibitus effectus laterum leukopeniae, diarrhoeae, nauseahromitationis et alopeciae exhibuit.Deducta therapia irinotecan cum alio agente late adhibito anticancer, cisplatina, relatum est esse superiorem vel soli agenti.lrinotecan in iudiciis clinicis gastrointestinis, pectoris, cutis, colorectalibus, carcinomata pancreatica, mesothelioma et lymphoma non-Hodgkin.
